Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionRockefeller Capital Management L.P.
Latest Disclosed Ownership149,655 shares
Latest Disclosed Value $ 66,827,375
Rockefeller Capital Management L.P. reports 10.67% increase in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On May 14, 2026 - Rockefeller Capital Management L.P. filed a 13F-HR form disclosing ownership of 149,655 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $66,826,944 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on March 16, 2026 disclosing 135,232 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 10.67% during the quarter. The current value of the position is $66,108,600 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 149,655 14,423 10.67 66,827 9.00 0.0614
2026-03-16 2025-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 135,232 42,418 45.70 61,309 68.67 0.1104
2026-02-14 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 136,581 43,767 61,310 0.0560
2025-11-14 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 92,814 -6,924 -6.94 36,350 -18.14 0.0711
2025-08-14 2025-06-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 99,738 8,774 9.65 44,404 0.68 0.0974
2025-08-08 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 99,700 8,736 44,387 0.1114
2025-05-14 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 90,964 -7,825 -7.92 44,101 10.85 0.1089
2025-02-13 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 98,789 28,240 40.03 39,784 21.26 0.1030
2024-11-14 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 70,549 -612 -0.86 32,808 -1.63 0.0883
2024-08-12 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 71,161 1,280 1.83 33,351 14.18 0.0948
2024-05-14 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 69,881 9,356 15.46 29,211 18.61 0.0853
2024-02-14 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 60,525 7,635 14.44 24,627 33.90 0.0823
2023-11-14 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 52,890 1,467 2.85 18,393 1.64 0.0709
2023-08-14 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 51,423 5,695 12.45 18,096 129,157.14 0.0701
2023-05-16 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 45,728 -1,816 -3.82 14 -99.90 0.0620
2023-03-06 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 47,544 -241 -0.50 13,729 -0.77 0.0690
2022-11-02 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 47,785 4,818 11.21 13,835 14.27 0.0715
2022-08-12 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 42,967 6,039 16.35 12,107 25.64 0.0643
2022-05-13 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 36,928 6,807 22.60 9,636 45.69 0.0465
2022-02-14 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 30,121 6,248 26.17 6,614 52.78 0.0309
2021-11-12 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 23,873 6,477 37.23 4,329 23.44 0.0227
2021-08-10 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 17,396 -1,346 -7.18 3,507 -12.91 0.0198
2021-05-11 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 18,742 7,191 62.25 4,027 47.62 0.0273
2021-02-12 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 11,551 599 5.47 2,728 -8.46 0.0207
2020-11-13 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 10,952 452 4.30 2,980 -2.23 0.0279
2020-08-12 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 10,500 2,282 27.77 3,048 55.91 0.0319
2020-05-12 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 8,218 5,987 268.35 1,955 300.61 0.0256
2020-02-07 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,231 210 10.39 488 42.69 0.0061
2019-11-12 2019-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,021 525 35.09 342 24.82 0.0046
2019-08-09 2019-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,496 -1,208 -44.67 274 -44.87 0.0038
2019-05-10 2019-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,704 2,122 364.60 497 417.71 0.0071
2019-02-12 2018-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 582 532 1,064.00 96 860.00 0.0017
2018-11-02 2018-09-30 13F Vertex Pharmaceuticals Common 92532F100 50 0 0.00 10 25.00 0.0002
2018-07-31 2018-06-30 13F Vertex Pharmaceuticals Common 92532F100 50 50 8 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.